search
Back to results

A Clinical Study to Assess the Efficacy and Safety of SED80 for Use in Cataract Surgery

Primary Purpose

Cataract in Inflammatory Ocular Disorders

Status
Completed
Phase
Phase 2
Locations
El Salvador
Study Type
Interventional
Intervention
Dexamethasone Dose 1
Dexamethasone Dose 2
Placebo Dose 1
Placebo Dose 2
Sponsored by
iDrop, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cataract in Inflammatory Ocular Disorders

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients undergoing traditional cataract surgery.

Exclusion Criteria:

  • Patients with unusual ocular conditions.

Sites / Locations

  • Centre De. Oftalmologia

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Placebo Comparator

Arm Label

Dexamethasone Dose 1

Dexamethasone Dose 2

Placebo Dose 1

Placebo Dose 2

Arm Description

Outcomes

Primary Outcome Measures

Ocular inflammation
Measuring Anterior Cell Count

Secondary Outcome Measures

Ocular Pain
Measuring patient ocular pain using an 11-point visual scale

Full Information

First Posted
September 23, 2020
Last Updated
January 12, 2021
Sponsor
iDrop, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04711213
Brief Title
A Clinical Study to Assess the Efficacy and Safety of SED80 for Use in Cataract Surgery
Official Title
A Phase 2 Clinical Study to Assess the Efficacy and Safety of SED80 for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
September 14, 2020 (Actual)
Primary Completion Date
October 31, 2020 (Actual)
Study Completion Date
November 15, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
iDrop, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients at least 40 years of age who are undergoing cataract surgery will be randomized to receive treatment with one of four groups of dexamethasone ophthalmic suspension or placebo eye drops to determine if the drops decrease inflammation and pain inside the eye and are safe after cataract surgery.
Detailed Description
"Patients undergoing traditional cataract surgery routinely develop inflammation and pain. This study will evaluate 4 arms of either dexamethasone or placebo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract in Inflammatory Ocular Disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomized to 2 active dosing groups and 2 corresponding dosing groups
Masking
Participant
Masking Description
Single Masked randomized study
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dexamethasone Dose 1
Arm Type
Active Comparator
Arm Title
Dexamethasone Dose 2
Arm Type
Active Comparator
Arm Title
Placebo Dose 1
Arm Type
Placebo Comparator
Arm Title
Placebo Dose 2
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Dexamethasone Dose 1
Intervention Description
Dexamethasone ophthalmic suspension dose 1
Intervention Type
Drug
Intervention Name(s)
Dexamethasone Dose 2
Intervention Description
Dexamethasone ophthalmic suspension dose 2
Intervention Type
Drug
Intervention Name(s)
Placebo Dose 1
Intervention Description
Placebo suspension dose 1
Intervention Type
Drug
Intervention Name(s)
Placebo Dose 2
Intervention Description
Placebo suspension dose 2
Primary Outcome Measure Information:
Title
Ocular inflammation
Description
Measuring Anterior Cell Count
Time Frame
Day 8
Secondary Outcome Measure Information:
Title
Ocular Pain
Description
Measuring patient ocular pain using an 11-point visual scale
Time Frame
Day 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing traditional cataract surgery. Exclusion Criteria: Patients with unusual ocular conditions.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gabriel Casada, MD
Organizational Affiliation
President - Centre De. Oftalmolgia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre De. Oftalmologia
City
San Salvador
Country
El Salvador

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Clinical Study to Assess the Efficacy and Safety of SED80 for Use in Cataract Surgery

We'll reach out to this number within 24 hrs